GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » WuXi XDC Cayman Inc (HKSE:02268) » Definitions » Free Cash Flow per Share

WuXi XDC Cayman (HKSE:02268) Free Cash Flow per Share : HK$-0.66 (TTM As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is WuXi XDC Cayman Free Cash Flow per Share?

WuXi XDC Cayman's Free Cash Flow per Share for the six months ended in Dec. 2024 was HK$-0.03. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-0.66.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the FCF Growth Rate using Free Cash Flow per Share data.

The historical rank and industry rank for WuXi XDC Cayman's Free Cash Flow per Share or its related term are showing as below:

During the past 5 years, WuXi XDC Cayman's highest 3-Year average Free Cash Flow per Share Growth Rate was -87.20% per year. The lowest was -87.20% per year. And the median was -87.20% per year.

HKSE:02268's 3-Year FCF Growth Rate is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 4.95
* Ranked among companies with meaningful 3-Year FCF Growth Rate only.

WuXi XDC Cayman Free Cash Flow per Share Historical Data

The historical data trend for WuXi XDC Cayman's Free Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi XDC Cayman Free Cash Flow per Share Chart

WuXi XDC Cayman Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Free Cash Flow per Share
-0.03 0.01 0.05 -0.21 -0.65

WuXi XDC Cayman Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Free Cash Flow per Share Get a 7-Day Free Trial 0.07 -0.09 -0.11 -0.63 -0.03

Competitive Comparison of WuXi XDC Cayman's Free Cash Flow per Share

For the Diagnostics & Research subindustry, WuXi XDC Cayman's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WuXi XDC Cayman's Price-to-Free-Cash-Flow Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where WuXi XDC Cayman's Price-to-Free-Cash-Flow falls into.


;
;

WuXi XDC Cayman Free Cash Flow per Share Calculation

Free Cashflow per Share is the amount of Free Cashflow per outstanding share of the company's stock.

Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company.

Note: GuruFocus does not calculate Free Cash Flow Per Share when Capital Expenditure is 0.

WuXi XDC Cayman's Free Cash Flow Per Share for the fiscal year that ended in Dec. 2024 is calculated as

Free Cash Flow Per Share(A: Dec. 2024 )
=(Cash Flow from Operations+Capital Expenditure)/Shares Outstanding (Diluted Average)
=(765.759+-1607.034)/1288.235
=-841.275/1288.235
=-0.65

WuXi XDC Cayman's Free Cash Flow Per Share for the quarter that ended in Dec. 2024 is calculated as

Free Cash Flow Per Share(Q: Dec. 2024 )
=(Cash Flow from Operations+Capital Expenditure)/Shares Outstanding (Diluted Average)
=(1005.623+-1049.875)/1290.599
=-44.252/1290.599
=-0.03

Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


WuXi XDC Cayman  (HKSE:02268) Free Cash Flow per Share Explanation

Free Cash Flow is very close to Warren Buffett's definition of Owner's Earnings, except that in Warren Buffett's Owner's Earnings, the spending for Property, Plant, and Equipment is only for maintenance (replacement), while in the Free Cash Flow calculation, the cost of new Property, Plant, and Equipment due to business expansion is also deducted. There, Free Cash Flow is more conservative than Owner's Earnings.

In Don Yacktman's calculation of forward rate of return, he uses Free Cash Flow for the calculation. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation.

This is what Yacktman said in his March 2012 interview - when the S&P 500 was at 1400:

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is because research shows that five years is the length of the typical business cycle.

Therefore, as of Dec24, WuXi XDC Cayman's Forward Rate of Return (Yacktman) % is

Forward Rate of Return (Yacktman) % (Dec24)=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/31+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Free Cash Flow within a report period can be affected by management's decisions of capital spending. Therefore, it is important to look at long term when it comes to Free Cash Flow.


WuXi XDC Cayman Free Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of WuXi XDC Cayman's Free Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


WuXi XDC Cayman Business Description

Traded in Other Exchanges
Address
No. 11 Xinhui Ring Road, Xinwu, Jiangsu Province, Wuxi, CHN
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.
Executives
Shang Hai He Quan Yao Ye Gu Fen You Xian Gong Si
He Quan Yao Ye Xiang Gang Tou Zi You Xian Gong Si
Shang Hai Yao Ming Kang De Xin Yao Kai Fa You Xian Gong Si
Wu Xi Yao Ming Kang De Xin Yao Kai Fa Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Morgan Stanley 2201 Interest of corporation controlled by you
Wuxi Biologics (cayman) Inc. 2101 Beneficial owner
Wuxi Apptec Co., Ltd.

WuXi XDC Cayman Headlines

No Headlines